Myeloma Trial, Recruiting NCT05136807 Sponsor: M.D. Anderson Cancer Center Condition: Myeloma
Back to Myeloma

Myeloma Trial, Recruiting

NCT05136807
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who have been diagnosed with a condition called monoclonal gammopathy of undetermined significance (MGUS), where certain protein levels in the blood or urine are below specific thresholds, less than 10% of bone marrow cells are abnormal plasma cells, and there are no signs of active myeloma or a related condition called amyloidosis
  • Adults aged 18 or older who have been diagnosed with smoldering multiple myeloma (SMM), where certain protein levels in the blood or urine meet or exceed specific thresholds and/or between 10–60% of bone marrow cells are abnormal plasma cells, and there are no signs of active myeloma or amyloidosis
  • People who are already enrolled in one of several specific clinical trials for MGUS or SMM at MD Anderson Cancer Center, or in any future MGUS or SMM trials that open at that centre (confirm with trial site for the full list of qualifying trials)
  • People who speak English or Spanish

Who may not be able to join:

  • People who show signs that their plasma cell condition has progressed to active myeloma, including: abnormally high calcium levels in the blood, poor kidney function, low red blood cell levels (anaemia), bone damage seen on imaging scans, 60% or more abnormal plasma cells in the bone marrow, a significantly abnormal ratio of certain proteins in the blood (free light chains), or more than one area of concern seen on MRI scans where each area is at least 5mm in size
  • People diagnosed with plasma cell leukaemia, a rare and aggressive blood cancer
  • People who have been assessed by their treating doctor as having significant cognitive impairment or delirium

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Melody E Becnel, M.D. Anderson Cancer Center

Phone: 832-206-9804

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
7 June 2016
Est. completion
2 February 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Quality of life questionnaires; Quality of life questionnaires

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov